Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASCO’s Value Framework
ASCO Value Framework Ill-Equipped to Assess Value of Therapies in Chronic Lymphocytic Leukemia
By
Chase Doyle
Economics & Value
,
Value-Based Care
,
ASCO’s Value Framework
February 2017, Vol 8, No 1
San Diego, CA—A study examining the feasibility and applicability of the American Society of Clinical Oncology (ASCO) Value Framework in chronic lymphocytic leukemia (CLL) suggests that the tool, although useful in assessing a small percentage of drug regimens, may need to be amended to be useful in CLL, reported Erlene K. Seymour, MD, Assistant Professor, Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, at the 2016 American Society of Hematology meeting.
Read Article
ASCO’s Value Framework: Is It All About the Drugs?
By
Avi Dor, PhD
;
Elizabeth Hoffler, MSW
;
Mandi Pratt-Chapman, MA
;
Eduardo Sotomayor, MD
Value in Oncology
,
ASCO’s Value Framework
October 2015, Vol 6, No 9
The American Society of Clinical Oncology (ASCO) recently issued its framework to assess the value of cancer treatment options in response to the major challenge of escalating healthcare costs in the United States.
Read Article
ASCO’s Value Framework Promoting Accountability and Transparency
By
Joseph Morse
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
,
ASCO’s Value Framework
August 2015, Vol 6, No 7
The American Society of Clinical Oncology (ASCO) value framework essentially calls for accountability and transparency, which are qualities that are beneficial to providing complete care for patients and to improving positive patient outcomes.
Read Article
ASCO Value Framework: A Step Forward or Back?
By
Ted Okon, MBA
ASCO’s Value Framework
,
VBCC Perspectives
,
Economics & Value
,
Value-Based Care
July 2015, Vol 6, No 6
With all the focus in the media on cancer drug costs, let alone within the oncology community, the American Society of Clinical Oncology (ASCO) has released its much-anticipated value framework.
Read Article
The ASCO Value Framework: To What End?
ASCO’s Value Framework
,
Value-Based Care
,
VBCC Perspectives
,
Economics & Value
July 2015, Vol 6, No 6
Read Article
ASCO’s Value Framework Abandons the Hippocratic Oath
By
Robert Goldberg, PhD
ASCO’s Value Framework
,
Value-Based Care
,
VBCC Perspectives
,
Economics & Value
July 2015, Vol 6, No 6
The American Society of Clinical Oncology (ASCO) new value framework abandons the Hippocratic Oath. No longer is the doctor’s first obligation to “apply, for the benefit of the sick, all measures which are required.” Instead, ASCO’s value framework has the potential to help insurers “evaluate the relative value of new treatments” as they develop “benefit structures, adjustment of insurance premiums, and implementation of clinical pathways and administrative controls."
Read Article
ASCO Develops New Framework to Evaluate the Value of Cancer Therapies
By
Laura Morgan
ASCO’s Value Framework
July 2015, Vol 6, No 6
Cancer care is one of the fastest growing components of US healthcare costs and is estimated to reach $158 billion by 2020. The American Society of Clinical Oncology (ASCO) Value in Cancer Care Task Force attributes the rising cost of cancer care to several factors, including the overall aging of the population, the introduction of costly new drugs and innovative surgery and radiation techniques, and the adoption of more expensive diagnostic tests.
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma